{"entity": "researcher", "timestamp": "2026-08-23T09:27:15.043Z", "family": "Schiza", "given": "Aglaia", "initials": "A", "orcid": "0000-0002-5514-3637", "affiliations": ["Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Dag Hammarskjoldsvag 20, 751 85, Uppsala, Sweden. aglaia.schiza@igp.uu.se.", "Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden. aglaia.schiza@igp.uu.se."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb"}}, "publications": [{"entity": "publication", "iuid": "9311a22f3e4148f1804247c12f78c8c7", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/9311a22f3e4148f1804247c12f78c8c7.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/9311a22f3e4148f1804247c12f78c8c7"}}, "title": "Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study.", "authors": [{"family": "Schiza", "given": "Aglaia", "initials": "A", "orcid": "0000-0002-5514-3637", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb.json"}}, {"family": "Fredriksson", "given": "Irma", "initials": "I"}, {"family": "Sund", "given": "Malin", "initials": "M"}, {"family": "Valachis", "given": "Antonios", "initials": "A"}], "type": "journal article", "published": "2024-01-00", "journal": {"title": "Breast Cancer Res. Treat.", "issn": "1573-7217", "volume": "203", "issue": "2", "pages": "235-243", "issn-l": "0167-6806"}, "abstract": "Evidence supporting the use of neoadjuvant chemotherapy (NAC) in early breast cancer is based on studies mainly including women, whereas the utilization and effectiveness of NAC in men is less studied. The present study aimed to investigate the utilization and effectiveness of NAC in men and women with early breast cancer.\n\nEligible patients were identified through the Swedish National Breast Cancer Quality Register, that includes all newly diagnosed breast cancer cases in Sweden from 2008 and onwards. For the treatment utilization analysis, all patients with stage I-III between 2008 and 2020 were included (n = 82,888), whereas for the effectiveness analysis the cohort was restricted to patients receiving NAC (n = 6487). For both analyses, multivariate logistic regression models were applied to investigate potential sex disparities in NAC utilization and effectiveness, adjusted for patient- and tumor characteristics.\n\nIn the NAC utilization analysis, 487 men and 82,401 women with stage I-III were included. No statistically significant difference between sexes in terms of NAC utilization was observed (adjusted Odds Ratio (adjOR): 1.135; 95% Confidence Interval (CI) 0.606-2.128) with an overall utilization rate of 4.9% in men compared to 7.8% in women. Among the 24 men and 6463 women who received NAC, the pathologic complete response (pCR) rates were 16.7% and 21.2%, respectively (adjOR: 1.141; 95% CI 0.141-9.238).\n\nThe present study did not find any sex disparities in NAC utilization or effectiveness in terms of pCR. This supports the current recommendations of treating men with breast cancer with the same indications for NAC as women.", "doi": "10.1007/s10549-023-07129-1", "pmid": "37812362", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10787884"}, {"db": "pii", "key": "10.1007/s10549-023-07129-1"}], "notes": [], "created": "2026-08-21T11:07:42.099Z", "modified": "2026-08-21T11:07:42.151Z"}, {"entity": "publication", "iuid": "f592dcda0e684595bc8de93d13589074", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f592dcda0e684595bc8de93d13589074.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f592dcda0e684595bc8de93d13589074"}}, "title": "Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.", "authors": [{"family": "Schiza", "given": "Aglaia", "initials": "A", "orcid": "0000-0002-5514-3637", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb.json"}}, {"family": "Mauri", "given": "Davide", "initials": "D"}, {"family": "Fredriksson", "given": "Irma", "initials": "I"}, {"family": "Valachis", "given": "Antonios", "initials": "A"}], "type": "journal article", "published": "2021-04-00", "journal": {"title": "Breast Cancer Res. Treat.", "issn": "1573-7217", "volume": "186", "issue": "3", "pages": "779-789", "issn-l": "0167-6806"}, "abstract": "There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC). The purpose of this population-based cohort study was to investigate the potential benefit of AIs compared to TAM as adjuvant therapy in postmenopausal BC patients by HER2-status in the era of modern therapy with HER2-blockade.\n\nA population-based cohort study was performed including all postmenopausal women diagnosed with HR-positive BC without distant metastasis between 2007 and 2012 in three healthcare regions in Sweden. We analyzed the breast cancer-specific survival (BCSS) and overall survival (OS) in two distinct cohorts (HER2-negative, HER2-positive) based on the type of endocrine therapy (ET) used. A propensity score matching was performed separately in the HER2-negative and HER2-positive cohorts, respectively.\n\nAfter propensity score matching, 4368 patients with HER2-negative and 214 patients with HER2-positive BC were available for analysis. In the HER2-negative cohort, an improved BCSS [Hazard Ratio (HR): 0.51; 95% confidence interval (CI): 0.34-0.77, p value < 0.001] and a trend toward improved OS (HR: 0.66; 95% CI: 0.41-1.08, p value = 0.093) in favor of AI-based therapy was observed. In the HER2-positive cohort, no statistically significant difference between AI-based ET and TAM was found in terms of either BCSS or OS, although the direction of HR was similar as in the HER2-negative cohort (HR for BCSS: 0.84; 95% CI: 0.14-5.04, p = 0.849; HR for OS: 0.62; 95% CI: 0.10-3.38, p = 0.345).\n\nOur study results, based on propensity-matched cohorts, did not support any predictive value of HER2-status on endocrine therapy in postmenopausal BC patients. AI-based ET remains the treatment of choice for postmenopausal BC patients with HR-positive disease in the modern era of HER2-directed therapy irrespective of HER2-status.", "doi": "10.1007/s10549-020-06022-5", "pmid": "33258078", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8019428"}, {"db": "pii", "key": "10.1007/s10549-020-06022-5"}], "notes": [], "created": "2026-08-21T11:07:37.501Z", "modified": "2026-08-21T11:07:37.568Z"}, {"entity": "publication", "iuid": "fd31f71a873f46dc84195eb06dd78d11", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/fd31f71a873f46dc84195eb06dd78d11.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/fd31f71a873f46dc84195eb06dd78d11"}}, "title": "Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.", "authors": [{"family": "Schiza", "given": "Aglaia", "initials": "A", "orcid": "0000-0002-5514-3637", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4a4589967d87426ba8587ddab8cbe8fb.json"}}, {"family": "Irenaeus", "given": "Sandra", "initials": "S"}, {"family": "Ortiz-Nieto", "given": "Francisco", "initials": "F"}, {"family": "Loskog", "given": "Angelica", "initials": "A", "orcid": "0000-0001-8583-6138", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/572e5b01b3bd48779252b9020732cb09.json"}}, {"family": "T\u00f6tterman", "given": "Thomas", "initials": "T"}, {"family": "Sundin", "given": "Anders", "initials": "A"}, {"family": "Ullenhag", "given": "Gustav J", "initials": "GJ"}, {"family": "Ahlstr\u00f6m", "given": "H\u00e5kan", "initials": "H"}], "type": "clinical trial, phase i", "published": "2019-12-02", "journal": {"title": "Sci Rep", "issn": "2045-2322", "volume": "9", "issue": "1", "pages": "18069", "issn-l": "2045-2322"}, "abstract": "The purpose was to evaluate the potential of diffusion-weighted-magnetic resonance imaging (DW-MRI) and 18F-fludeoxy-glucose-positron emission tomography integrated with CT (FDG-PET/CT) for prediction of overall survival (OS) following AdCD40L-immunotherapy in patients with metastatic malignant melanoma (MMM). Twenty-four patients with refractory MMM were treated with immunostimulatory AdCD40L gene therapy in a phase I/IIa study. Pre-therapeutic DW-MRI and FDG-PET/CT were performed and then repeated at 5 and 9 weeks post-treatment. Evaluation was conducted according to RECIST 1.1 and EORTC criteria. Apparent diffusion coefficient (ADC), true diffusion coefficient (D), maximum standardized uptake value (SUVmax) were measured in the injected lesions. Fold changes (F) in ADC (F ADC), D (F D), SUVmax (F SUVmax) were statistically assessed. F D \u2265 1 and F ADC \u2265 1 were associated with better OS in scans at week 5 and 9 respectively. F SUVmax was not correlated to OS. F ADC \u2265 1 in both post-treatment scans and F D \u2265 1 at week 5 were related to a significant decrease of size of the injected lesions. These results suggest that in patients with MMM treated with AdCD40l, functional parameters of DW-MRI are better early predictors of OS than the established metabolic and morphologic criteria for FDG-PET/CT and MRI, respectively.", "doi": "10.1038/s41598-019-54438-x", "pmid": "31792256", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6889008"}, {"db": "pii", "key": "10.1038/s41598-019-54438-x"}], "notes": [], "created": "2026-08-21T11:52:58.595Z", "modified": "2026-08-21T11:52:58.674Z"}]}